Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 3865Neoplasms 2990Prostatic Neoplasms 1754Colorectal Neoplasms 1431Lung Neoplasms 1331Motor Activity 805Head and Neck Neoplasms 686Pancreatic Neoplasms 663Colonic Neoplasms 655Uterine Cervical Neoplasms 653Carcinoma, Hepatocellular 632Carcinoma, Non-Small-Cell Lung 631Rectal Neoplasms 571Stomach Neoplasms 547Brain Neoplasms 486Ovarian Neoplasms 441Anxiety Disorders 420Pain 419Neoplasm Metastasis 385Esophageal Neoplasms 384Polycystic Ovary Syndrome 376Precursor Cell Lymphoblastic Leukemia-Lymphoma 354Urinary Bladder Neoplasms 351Fatigue 340Melanoma 323Multiple Myeloma 322Lymphoma 306Depression 306Endometrial Neoplasms 290Liver Neoplasms 280

Interventions

tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Interventional × Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder) × Clear all
NCT06154967 2023-12-04

To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase NA Unknown
20 enrolled
Thoracic

Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡